$MRK KEYTRUDAÂ Reduced Risk of Death by 31 Compared to Chemo in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PDL1 httpswww.businesswire.comnewshome20190114005813enMerckE280

$MRK KEYTRUDA® Reduced Risk of Death by 31 % Compared to Chemo in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 https://www.businesswire.com/news/home/20190114005813/en/Merck%E2%80

17:01 EST 14 Jan 2019 | Odi Bruckman

$MRK KEYTRUDA® Reduced Risk of Death by 31 % Compared to Chemo in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 https://www.businesswire.com/news/home/20190114005813/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Reduced-Risk-Death-31 …

More From BioPortfolio on "$MRK KEYTRUDA® Reduced Risk of Death by 31 % Compared to Chemo in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 https://www.businesswire.com/news/home/20190114005813/en/Merck%E2%80"